CollPlant to Present Results of its Product for the Treatment in Tendinopathy, at the 4th TERMIS Congress Which Will Take Place in Boston

News provided by

Sep 08, 2015, 11:47 ET

NESS ZIONA, Israel, September 8, 2015 /PRNewswire/ --

CollPlant (TASE:CLPT), a clinical stage regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, announced today that Dr. Nadav Orr, the company's Vice President for R&D and Dr. Jasmin Seror, the company's Product Manager, will present results of the Vergenix™STR preclinical studies at the 4th TERMIS (Tissue Engineering and Regenerative Medicine International Society). Vergenix™STR is an injectable gel composed of human recombinant type I collagen used in combination with autologous platelet rich plasma (PRP) for the treatment of a range of tendon injuries. Following injection into the injured site, Vergenix™STR transitions from a fluid to a solid phase, whereupon, platelet-derived proteins are released, in a controlled fashion, and induce the healing effect on the tendon.

The results will be presented on Wednesday, September 9th 2015, afternoon as part of a poster session. Dr. Jasmine Seror will present that Vergenix™STR combined with PRP shows superior performance compared to PRP alone. The congress is being held at the Boston Marriott Copley Place Hotel in Boston U.S.A., on September 8th-11th.

Vergenix™STR is currently completing its clinical trial in anticipation of filing for CE marketing approval later this year. Interim clinical results released in July 2015, for the first 10 patients who reached their three month follow up, indicate that 80% of subjects reported improvement in pain and arm functionality, including increase in arm strength.

About CollPlant

CollPlant is a clinical-stage regenerative medicine company leveraging its proprietary, plant-based rhCollagen technology for the development and commercialization of tissue repair products, initially for the orthobiologics and advanced wound care markets. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds, and; Vergenix™BVF (Bone Void Filler), for use in spinal fusion procedures and trauma. CollPlant's business strategy includes proprietary development and manufacturing of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional products. For more information about CollPlant, visit http://www.collplant.com

Contact at CollPlant:
Eran Rotem
Chief Financial Officer
Tel: + 972-73-2325600/612
Email: [email protected]

Contact at Rx Communications Group, LLC:
Paula Schwartz (for US Investors)
Tel: 917-322-2216
Senior Vice President
Email: [email protected]